格菲妥单抗(Glofitamab) - 药物靶点：CD20 x CD3_在研适应症：复发性弥漫性大B细胞淋巴瘤，难治性弥漫性大 B 细胞淋巴瘤，弥漫性大B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

双特异性T细胞结合器

别名

Anti-CD20/CD3 bispecific monoclonal antibody、Anti-CD20/CD3 bispecific monoclonal antibody RO7082859、Glofitamab (USAN/INN)

+ [14]

靶点

CD20 x CD3

作用方式

抑制剂、刺激剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)、ADCC(抗体依赖的细胞毒作用)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [2]

在研适应症

复发性弥漫性大B细胞淋巴瘤难治性弥漫性大 B 细胞淋巴瘤弥漫性大B细胞淋巴瘤+ [27]

非在研适应症-

原研机构

F. Hoffmann-La Roche Ltd.

在研机构

Eli Lilly & Co.

Roche Holding AG

Genentech, Inc.

+ [9]

非在研机构-

权益机构

Biogen, Inc.

Genentech, Inc.

最高研发阶段批准上市

首次获批日期

加拿大 (2023-03-24),

弥漫性大B细胞淋巴瘤滤泡性淋巴瘤高级别B细胞淋巴瘤+ [1]

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (澳大利亚)、附条件批准 (欧盟)、突破性疗法 (中国)、优先审评 (美国)、附条件批准 (中国)、附条件批准 (加拿大)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 10044005

来源: *****

Sequence Code 10044025

来源: *****

Sequence Code 616723731

来源: *****

Sequence Code 616723732

来源: *****

关联

111

项与格菲妥单抗相关的临床试验

NCT07634289

/ Not yet recruiting临床2期IIT

Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Phase II Radio-GLO Study

The goal of this clinical trial is to see if a new combination of standard of care radiotherapy treatment prior to administering the study drugs obinutuzumab and glofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma patients is effective. The main question it aims to answer is:
If you are able to tolerate the study treatments, and whether your cancer responds to the study treatment, compared with other reported studies of standard care treatments.
Participants will have three parts they need to complete over a 5 year period.
* Screening period over a 28 day period
* Treatment period - Radiotherapy followed by 12 treatment cycles every three weeks (total time approx. 37 weeks)
* Follow up, up to 4 years. Additional PET imaging studies will be performed in a cohort of patients (up to 6) who are willing to undergo infusions of 89Zr-Df-Crefmirlimab and 18F-Granzyme B for evaluation of the impact of radiotherapy plus glofitamab with relapsed diffuse large B-cell lymphoma.

开始日期2026-12-01

申办/合作机构

Olivia Newton-John Cancer Research Institute

[+5]

NCT07502872

/ Not yet recruiting临床2期IIT

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).

开始日期2026-11-01

申办/合作机构

Brown University

[+3]

NCT07724457

/ Not yet recruiting临床2/3期IIT

A Randomized Phase 2/3 Study the Bispecific Antibody (BsAb), Glofitamab, Plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade (Double Hit) B-Cell Lymphomas With MYC and BCL2 Rearrangements

This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Glofitamab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Obinutuzumab and rituximab are also monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cytarabine and ifosfamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab with standard of care chemotherapy may work well for the treatment of newly diagnosed, relapsed or refractory Burkitt and high grade (double hit) B- cell lymphomas.

开始日期2026-10-30

申办/合作机构

National Cancer Institute

100 项与格菲妥单抗相关的临床结果

登录后查看更多信息

100 项与格菲妥单抗相关的转化医学

登录后查看更多信息

100 项与格菲妥单抗相关的专利（医药）

登录后查看更多信息

160

项与格菲妥单抗相关的文献（医药）

2026-08-11·Blood Advances

“Immunologic dream team”: BiTEs periallotransplant to redirect donor lymphocytes toward GVL

Article

作者: Milano, Filippo ; Shadman, Mazyar ; Gopal, Ajay K. ; Iovino, Lorenzo

Abstract:

Bispecific T-cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B-cell lymphomas and multiple myeloma otherwise resistant to other therapies, but the duration of response to these treatments is limited in time. Allogeneic stem cell transplantation is a potentially curative approach for those disorders, although its indication is limited to patients who achieve remission. With no established strategies to improve the “graft-versus-tumor effect” available, relapses still account for most posttransplant failures. Here, we report, to our knowledge, the first case in literature of a successful treatment with glofitamab, a CD20X2/CD3 BiTE, in a posttransplant relapse of mantle cell lymphoma with central nervous disease involvement. We propose the combination of BiTEs and allogeneic transplant as an integrated and sequential immunologic approach to be tested in clinical trials.

2026-08-11·Blood Advances

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO

Article

作者: Ghesquières, Hervé ; Huang, Hui-Qiang ; Chang, Hung ; Belousov, Anton ; Kim, Won Seog ; Kallemeijn, Martine ; Zaucha, Jan M. ; Fox, Christopher P. ; Mulvihill, Estefania ; Lundberg, Linda ; Bottos, Alessia ; Choeurng, Voleak ; Zhang, Huilai ; Zhang, Qing-Yuan ; Cheah, Chan Yoon ; Gregory, Gareth P. ; Ta, Richard ; Abramson, Jeremy S. ; Yoon, Dok Hyun ; Herbaux, Charles ; Hertzberg, Mark ; Townsend, William ; Liu, Yanyan ; Ku, Matthew ; Kesavan, Murali ; Relf, James ; Abdulhaq, Haifaa

Abstract:

In the phase 3 STARGLO trial, glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) demonstrated superior overall survival (OS) vs rituximab plus GemOx (R-GemOx), in patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We present efficacy and safety from STARGLO, with 3 years of follow-up, including in clinically relevant subgroups. After a median OS follow-up of 35.1 months (data cutoff: 1 May 2025), Glofit-GemOx continued to demonstrate favorable outcomes vs R-GemOx, respectively: median OS, 25.5 vs 12.5 months (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.4-0.8); median progression-free survival, 14.4 vs 3.3 months (HR, 0.41; 95% CI, 0.3-0.6); complete response rate, 58.5% vs 25.3%. Glofit-GemOx was particularly efficacious in the second-line (2L) vs third-line or later setting (3-year OS rate, 54.6% [95% CI, 45.2-64.0] vs 33.2% [95% CI, 21.2-45.3]). In the 2L setting, among patients with primary refractory disease or early treatment failure, the 36-month OS rate was 46.1% (95% CI, 35.2-56.9) with Glofit-GemOx vs 16.5% (95% CI, 3.4-29.6) with R-GemOx. Glofit-GemOx was favorable over R-GemOx regardless of patient age, with consistent efficacy observed across age categories, including in older patients (aged ≥75 years). No new safety signals were identified. With extended follow-up, fixed-duration Glofit-GemOx continues to demonstrate superior survival vs R-GemOx in ASCT-ineligible patients with R/R DLBCL, with favorable outcomes pronounced in the 2L setting, and consistent across subgroups including older patients and those with early relapsing disease. These data support Glofit-GemOx as an effective off-the-shelf treatment with curative potential in R/R DLBCL. This trial was registered at www.clinicaltrials.gov as NCT04408638.

2026-08-03·Expert Opinion on Drug Discovery

Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas

Review

作者: Salles, Gilles ; Berning, Philipp

INTRODUCTION:

Relapsed/refractory (R/R) large B-cell lymphoma (LBCL) remains a clinical challenge, particularly for patients with primary refractory or relapsed disease and ineligible for cellular therapies. T-cell engagers in the form of CD20xCD3 bispecific antibodies (BsAb) offer an effective 'off-the-shelf' therapy option that redirects endogenous T cells against malignant B cells.

AREAS COVERED:

This review summarizes the preclinical and translational development of glofitamab, a full-length 2:1 BsAb, focusing on R/R LBCL. The authors discuss the molecular design rationale, mechanism of action, and preclinical efficacy that enabled clinical translation. They review clinical development milestones across monotherapy and combination regimens in heavily pretreated R/R LBCL, activity after CAR T-cell therapy, and data supporting movement into earlier lines and strategies for older/unfit patients. This article is based on clinical trial reports and major trial registrations in B-cell lymphomas obtained via PubMed and ClinicalTrials.gov, covering literature published up to January 2026.

EXPERT OPINION:

Glofitamab provides clinically meaningful, time-limited treatment achieving disease control in patients who are ineligible for autologous HCT and/or CAR T-cell therapy and for those relapsing after CAR T-cell therapy. Future research will be needed on biomarker-guided sequencing, optimized toxicity/infection mitigation, and combination strategies that improve durable response rates.

969

项与格菲妥单抗相关的新闻（医药）

2026-09-16

·手机新浪网

必贝特跌0.76%，成交额7389.12万元，近3日主力净流入185.39万

9月16日，必贝特跌0.76%，成交额7389.12万元，换手率4.92%，总市值94.01亿元。异动分析减肥药+细胞免疫治疗+创新药+科创次新股+注册制次新股1、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。2、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。3、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。4、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-367.96万，占比0.05%，行业排名110/157，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-6.40亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-367.96万185.39万-267.71万-4397.52万-6037.74万主力持仓主力没有控盘，筹码分布非常分散，主力成交额1900.40万，占总成交额的7.14%。技术面：筹码平均交易成本为24.02元该股筹码平均交易成本为24.02元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位20.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、生物医药、抗癌药物、细胞免疫治疗、抗癌治癌等。截至8月20日，必贝特股东户数1.07万，较上期减少2.91%；人均流通股6737股，较上期增加2.99%。2026年1月-6月，必贝特实现营业收入0.00元；归母净利润-9737.66万元，同比减少31.78%。机构持仓方面，截止2026年6月30日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股165.01万股，相比上期减少47.75万股。长城消费增值混合A（200006）位居第五大流通股东，持股80.70万股，相比上期增加2789.00股。博时天颐债券A（050023）位居第七大流通股东，持股76.09万股，相比上期减少36.32万股。华宝生态中国混合A（000612）、大摩健康产业混合A（002708）退出十大流通股东之列。

2026-09-15

·研发客

GSK收购恩沐生物TCE资产，2027年进入Ⅰ期临床

9月15日， GSK宣布与恩沐生物（Chimagen Biosciences）达成协议，收购一款潜在的同类最佳三特异性T细胞衔接器（TCE），针对多发性骨髓瘤治疗。该项目将于2027年进入I期临床。GSK负责该资产的开发及商业化。根据协议条款，GSK将支付一笔前期费用，以获得TCE项目的全球全部权利。恩沐生物还将有资格获得开发及商业化里程碑付款。潜在交易价值最高7.5亿美元。来源|GSK官网目前，针对多发性骨髓瘤已有多款TCE 产品上市，包括强生teclistamab、罗氏glofitamab、辉瑞elranatamab。据GSK报道显示，恩沐生物这款TCE候选药物可同时结合T细胞以及两个经策略性筛选和验证的肿瘤相关抗原，这种靶向设计有望实现比现有TCE更深入、更持久的治疗反应，并改善整体耐受性，将有助于在多发性骨髓瘤治疗中实现更广泛的应用和更早的使用，为根据治疗需求可能需要多种选择的患者带来重要进展。预计到2032年，美国多发性骨髓瘤的TCE市场将超过100亿美元。此次协议建立在双方已有合作的基础之上。此前，GSK与恩沐生物达成协议，收购CMG1A46——一种靶向CD19和CD20的T细胞衔接器（TCE），目前正在针对B细胞恶性肿瘤及B细胞依赖性自身免疫性疾病开展I期临床试验。拓展阅读 3亿美元预付款！GSK收购恩沐生物一款TCE 总第3141期访问研发客网站www.PharmaDJ.com 深度报道和每日新闻抢鲜看

并购临床1期临床2期

2026-09-15

·手机新浪网

必贝特涨0.38%，成交额5196.83万元，后市是否有机会？

9月15日，必贝特涨0.38%，成交额5196.83万元，换手率3.42%，总市值94.73亿元。异动分析减肥药+细胞免疫治疗+创新药+科创次新股+注册制次新股1、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。2、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。3、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。4、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入265.29万，占比0.05%，行业排名14/157，连续2日被主力资金增仓；所属行业主力净流入-9.56亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入265.29万28.92万-773.44万-4070.98万-5354.05万主力持仓主力没有控盘，筹码分布非常分散，主力成交额2152.29万，占总成交额的6.76%。技术面：筹码平均交易成本为24.19元该股筹码平均交易成本为24.19元，近期筹码快速出逃，建议调仓换股；目前股价靠近支撑位20.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、生物医药、抗癌药物、抗癌治癌、细胞免疫治疗等。截至8月20日，必贝特股东户数1.07万，较上期减少2.91%；人均流通股6737股，较上期增加2.99%。2026年1月-6月，必贝特实现营业收入0.00元；归母净利润-9737.66万元，同比减少31.78%。机构持仓方面，截止2026年6月30日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股165.01万股，相比上期减少47.75万股。长城消费增值混合A（200006）位居第五大流通股东，持股80.70万股，相比上期增加2789.00股。博时天颐债券A（050023）位居第七大流通股东，持股76.09万股，相比上期减少36.32万股。华宝生态中国混合A（000612）、大摩健康产业混合A（002708）退出十大流通股东之列。

100 项与格菲妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11833	-	-	DB16371

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性弥漫性大B细胞淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-25
难治性弥漫性大 B 细胞淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-25
弥漫性大B细胞淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-24
滤泡性淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-24
高级别B细胞淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-24
纵隔大b细胞淋巴瘤	加拿大	Hoffmann-La Roche Ltd.	2023-03-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
套细胞淋巴瘤	临床3期	美国	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	中国	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	澳大利亚	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	巴西	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	加拿大	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	法国	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	意大利	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	韩国	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	西班牙	罗氏（中国）投资有限公司	2023-10-09
套细胞淋巴瘤	临床3期	瑞典	罗氏（中国）投资有限公司	2023-10-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04980222 (Phase II open-label prospective trial, CTgov)	临床2期	弥漫性大B细胞淋巴瘤	46	Cyclophosphamide+prednisone+Tocilizumab+Doxorubicin+Glofitamab+Rituximab+Vincristine	襯網願鑰鹽遞築積鹽觸 = 獵製願鏇鏇簾蓋顧構選築選鑰選簾鏇觸窪築蓋 (窪壓製觸觸衊鑰蓋襯鬱, 遞範範醖醖鏇淵廠淵觸 ~ 醖遞遞糧選選範膚蓋簾) 更多	-	2026-08-18
NCT04703686 (LYSA BiCAR, Pubmed \| J Hematol Oncol)	临床2期	弥漫性大B细胞淋巴瘤 CD20-positive	47	Glofitamab (CD20-positive Diffuse Large B-Cell Lymphoma + Refractory or first relapse after anti-CD19 CAR T-cell therapy)	願艱網鹽醖顧艱鬱鏇選(廠艱淵壓廠構構壓鏇鑰) = 顧簾壓蓋簾鏇廠齋繭醖製選繭範齋鏇製壓繭網 (壓繭積觸網顧衊鏇願膚 ) 更多	积极	2026-07-01
				Non-bispecific systemic therapy (CD20-positive Diffuse Large B-Cell Lymphoma + Refractory or first relapse after anti-CD19 CAR T-cell therapy)	願艱網鹽醖顧艱鬱鏇選(廠艱淵壓廠構構壓鏇鑰) = 網鹹襯淵繭鬱鏇繭壓獵製選繭範齋鏇製壓繭網 (壓繭積觸網顧衊鏇願膚 )
ASCO2026	N/A	B细胞淋巴瘤	63	Glofitamab	齋鹹觸網構糧衊製憲積(鏇積構夢膚醖觸襯選鏇) = 窪積鏇構構膚鬱構繭淵構網醖構餘網衊蓋繭鏇 (顧糧餘簾鹽膚蓋窪齋醖 ) 更多	积极	2026-05-29
				Epcoritamab	齋鹹觸網構糧衊製憲積(餘蓋衊鏇廠窪顧鹽構範) = 淵壓鑰獵餘簾淵襯鬱鏇顧壓鏇鏇壓夢遞鹽鹽鬱 (獵鑰鏇觸範艱觸鬱鏇糧 ) 更多
NCT03075696 (ASCO2026)	临床1/2期	套细胞淋巴瘤	60	Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamab + Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamabab 1000mg + Obinutuzumab 1000mgObinutuzumab 2000mgGlofitamabab 2000mg	範築壓鹽糧顧齋糧築壓(顧範蓋窪齋鏇餘積夢製) = 繭蓋網艱選衊蓋廠壓憲憲簾範壓憲憲衊憲鹽鬱 (鹽餘積簾鏇獵淵繭鹹觸 ) 更多	积极	2026-05-29
				Obinutuzumab 2000mg (prior BTKi therapy)	範築壓鹽糧顧齋糧築壓(顧範蓋窪齋鏇餘積夢製) = 繭構糧獵範築鬱憲觸願憲簾範壓憲憲衊憲鹽鬱 (鹽餘積簾鏇獵淵繭鹹觸 ) 更多
ASCO2026	N/A	弥漫性大B细胞淋巴瘤	936	CAR T-cell therapy	壓襯壓壓製獵鬱淵鹽鬱(網夢簾構廠積鑰夢網觸) = 獵衊簾繭糧糧艱積餘艱廠齋憲壓醖鬱壓顧憲簾 (願願窪築築構製獵積鑰 ) 更多	积极	2026-05-29
				Bispecific antibodies	壓襯壓壓製獵鬱淵鹽鬱(網夢簾構廠積鑰夢網觸) = 艱簾醖獵衊鏇鹹醖鬱顧廠齋憲壓醖鬱壓顧憲簾 (願願窪築築構製獵積鑰 ) 更多
NCT06393738 (ASCO2026)	临床1期	非霍奇金淋巴瘤 \| 弥漫性大B细胞淋巴瘤	255	ARV-393 (relapsed or refractory B-cell NHL or nTFHL)	觸鏇衊獵夢壓憲鑰鹽範(網齋餘選窪網窪鏇顧廠) = 餘鹽齋範襯齋壓獵繭鏇艱鑰鬱壓願鏇構壓繭壓 (網鑰範鹽網壓壓齋範醖 )	积极	2026-05-29
ASCO2026	N/A	复发性弥漫性大B细胞淋巴瘤	410	epcoritamab	襯製憲廠鑰鬱願膚積糧(積齋壓構範鬱憲遞齋觸) = 19.0% vs 25.4% 遞廠繭製鬱蓋顧願鏇網 (齋範糧廠窪鬱獵膚齋襯 ) 更多	积极	2026-05-29
				glofitamab
ASCO2026	N/A	急性淋巴细胞白血病 \| 小细胞癌 \| B细胞淋巴瘤 ... 更多	3,642	bispecific T-cell engager therapy	壓願窪襯顧衊鏇艱艱積(襯廠糧選積憲齋壓鏇築) = 齋壓艱製網糧觸鹹選齋繭鏇襯憲築廠簾壓鬱廠 (齋鏇廠窪獵鹹繭廠衊鬱 ) 更多	积极	2026-05-29
NCT03075696 (EHA2026)	临床1/2期	难治性套细胞淋巴瘤	61	Glofitamab	觸鬱選獵餘齋醖鹹壓觸(簾糧範選鹽窪鏇糧壓積) = Cytokine release syndrome remained the most common adverse event (all Grade, n=42/60, 70%; Grade 1-2, 58.3%; Grade 3-4, 11.6%; no Grade 5 events), with lower rates reported in the 2000mg Gpt cohort (n=28/44, 63.6%) compared with the 1000mg Gpt cohort (n=14/16, 87.5%). 鹽糧鹹窪憲鏇鹹簾簾齋 (獵築觸齋窪顧鏇窪獵願 )	积极	2026-05-21
				Glofitamab (received prior BTKi therapy)
EHA2026	N/A	大B细胞淋巴瘤	324	GLOFITAMAB	廠鏇醖餘鏇糧淵簾襯範(襯範淵觸壓衊願簾繭選) = 遞醖襯衊憲憲遞糧餘衊糧憲積衊構廠繭顧憲衊 (範蓋醖繭憲艱製簾壓簾 ) 更多	积极	2026-05-12
				EPCORITAMAB	廠鏇醖餘鏇糧淵簾襯範(襯範淵觸壓衊願簾繭選) = 簾鬱齋壓鑰餘鬱願鑰齋糧憲積衊構廠繭顧憲衊 (範蓋醖繭憲艱製簾壓簾 ) 更多